ANI Pharmaceuticals Inc. (NASDAQ:ANIP) shares are down early Friday following the company’s strong fourth-quarter report.
ANI Pharmaceuticals reported adjusted earnings of $2.33 per share, up from $1.63 a year ago, beating the consensus of $2.00.
Total net revenues for the fourth quarter reached $247.1 million, marking a 29.6% increase compared to the same period last year. The sales surpassed the consensus estimate of $231.53 million.
The Rare Disease segment, which includes products like Cortrophin Gel, saw a remarkable 50.8% growth, contributing $131.3 million to the overall revenue.
In addition, ANI reported a net income of $27.5 million for the fourth quarter, translating to $1.18 per diluted share, a significant turnaround from a net loss of $10.7 million in the prior year.
Adjusted EBITDA for the fourth quarter of 2025 was $65.4 million, an increase of 30.6% from the fourth quarter of 2024.
Expects Over $1 Billion In 2026 Sales
“2025 was a year of significant growth for our …